Clinical Trials

Beaumont Health System, with three hospitals in the northern Detroit suburbs serving southern Michigan and beyond, is a highly productive contributor to clinical trials across the nation. The Beaumont Research Institute, established by the hospital’s Board of Trustees in 1966, strengthens Beaumont's ability to conduct medical research and to provide a research training experience for the medical staff and participants in graduate medical education programs.

Unpublished
n/a

A RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH ONCE-DAILY LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES (AWARD-6: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-6)

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes (AWARD-6)

Status: open and enrolling

Approval Date: 8/23/2012

The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.


A RANDOMIZED, OPEN-LABEL, PARALLEL-ARM STUDY COMPARING THE EFFECT OF ONCE-WEEKLY DULAGLUTIDE WITH ONCE-DAILY LIRAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES (AWARD-6: ASSESSMENT OF WEEKLY ADMINISTRATION OF LY2189265 IN DIABETES-6)

A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes (AWARD-6)

Status: open and enrolling

Approval Date: 8/23/2012

The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.


[PROTOCOL MK7655-003] A PHASE II, RANDOMIZED, ACTIVE COMPARATOR-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY, TOLERABILITY, AND EFFICACY OF MK-7655 + IMIPENEM/CILASTATIN VERSUS INIPENEM/CILASTATIN ALONE IN PATIENTS WITH COMPLICATED URINARY TRACT INFECTI

MERCK 7655 003 Treatment of complicated UTI

Status: open and enrolling

Approval Date: 7/19/2012

The purpose of this study is to determine whether adding doses of a new drug to standardly prescribed imipenem/cilastatin is as effective as imipenem/cilastatin alone in adults 18 years or older with Complicated Urinary Tract Infection (cUTI).


[PROTOCOL MK7655-004] A PHASE II, RANDOMIZED, ACTIVE COMPARATOR-CONTROLLED CLINICAL TRIAL TO STUDY THE SAFETY, TOLERABILITY, AND EFFICACY OF MK-7655 + IMIPENEM/CILASTATIN VERSUS IMIPENEM/CILASTATIN ALONE IN PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFEC

MERCK 7655 004:cIAI

Status: open and enrolling

Approval Date: 7/19/2012

The purpose of this study is to determine whether adding doses of a new drug to standardly prescribed imipenem/cilastatin is as effective as imipenem/cilastatin alone in adults 18 years or older with Complicated Intra-Abdominal Infection (cIAI).